Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV

NCT00295477 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

GENETIC: VRX496

Sponsor

University of Pennsylvania

Collaborators

[object Object]